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Abstract: Impaired physical performance is common in chronic obstructive pulmonary 
disease (COPD), but its assessment can be difficult in routine clinical practice. We compared 
the timed up and go (TUG) test and other easily applied assessments of physical performance 
with the 6-minute walk distance (6MWD). In a longitudinal study of comorbidities in COPD, 
submaximal physical performance was determined in 520 patients and 150 controls using the 
TUG test and 6MWD. Spirometry, body composition, handgrip strength, the COPD assess-
ment test, St George’s Respiratory Questionnaire (SGRQ), and the modified Medical Research 
Council dyspnoea scale were also determined. Patients and controls were similar in age, body 
mass index, and sex proportions. The TUG in the patients was greater than that in the control 
group, P=0.001, and was inversely related to 6MWD (r=-0.71, P,0.001) and forced expira-
tory volume in one second predicted (r=-0.19, P,0.01) and was directly related to the SGRQ 
activity (r=0.39, P,0.001), SGRQ total (r=0.37, P,0.001), and total COPD assessment test 
scores (r=0.37, P,0.001). The TUG identified the difference in physical performance between 
patients and controls. The TUG test and validated questionnaires provide a measure of physical 
performance, which is rapid and could be used in clinical practice.
Keywords: COPD, physical inactivity, timed up and go test
Background
A major impact of chronic obstructive airway disease is the progressive loss of physical 
performance, which may lead to disability with loss of the ability to perform routine 
activities of daily living.1,2 Reduced physical activity occurs even in mild severity 
airflow obstruction as demonstrated by continuous activity monitoring where patients 
spend less time walking and standing than healthy controls.3,4 In addition to the impact 
on functional status, physical inactivity is associated with a reduced health-related 
quality of life (HR-QoL) and contributes to loss of muscle mass, increased systemic 
inflammation, osteoporosis, and cardiovascular disease, all comorbidities of chronic 
obstructive pulmonary disease (COPD).5,6 Consequently, it becomes a part of a vicious 
cycle of physical inactivity and changes in body composition that affect physical 
performance.5
The assessment of physical performance in patients with COPD in routine clinical 
practice is challenging and is often poorly quantified. Routine measurement of lung 
function, particularly the forced expiratory volume in 1 second (FEV
1
), cannot predict 
the level of physical impairment. Physical inactivity has detrimental changes on body 
composition, including musculoskeletal wasting, which could have major impacts on 
HR-QoL. Earlier lifestyle interventions in the disease may maintain physical activity 
levels and a normal body composition.7
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Physical performance in COPD has been assessed by 
various methods including questionnaires, which may 
have limited reproducibility and validity due to their 
dependence on patient recall. Quantitative measures of 
physical performance including 6-minute walking distance 
(6MWD), incremental shuttle walk test, and cycle ergom-
etry are available but require substantial time, space, and 
expertise.8,9 The 6MWD is a validated measure of submaxi-
mal physical performance and reflects daily activities, but 
only commonly used in clinical research.10 The timed up 
and go (TUG) test is a relatively simple and reproducible 
test that assesses balance, gait speed, and physical perfor-
mance and can predict of the risk of falls in COPD and 
elderly.11,12 However, the application of TUG in clinical 
practice is very limited, and only one study showed that 
TUG is feasible to be incorporated in the assessment of 
functions in patients with COPD.13 Thus, TUG may reflect 
routine daily activities, which require the integration of 
strength and balance. 
We hypothesized that patients with COPD would 
have greater TUG than a non-COPD control population. 
Additionally, that, TUG would be related to 6MWD and 
other assessments of physical performance in a similar way 
to that reported in elderly individuals. The aim of this study 
was to examine the use of TUG test in COPD as a measure 
of physical performance and its association with 6MWD and 
other validated outcome measures in COPD.
Methods
subjects
We assessed 520 patients with COPD, which was con-
firmed with spirometry and 150 controls, either current or 
ex-smokers free from cardiorespiratory and inflammatory 
diseases.14 This was a cross-sectional analysis from an ongo-
ing longitudinal study of comorbidities and cardiovascular 
risk in COPD, Assessment of Risk in Chronic Airways 
Disease Evaluation (ARCADE, Clinical Trials No NCT 
01656421). Patients were recruited when clinically stable 
and at least 4 weeks from an exacerbation of respiratory 
symptoms and free from other inflammatory diseases such 
as rheumatoid arthritis and inflammatory bowel disease. 
Controls were recruited from previous research databases 
carried out at the research centre and participant’s rela-
tives. The inclusion and exclusion criteria were previously 
published in the protocol paper of the ARCADE study.15 
All the subjects gave written informed consent, and the 
study had approval from the South East Wales Research 
Ethics Committee.
anthropometry and body composition 
measurement
All the subjects had their height measured barefoot using a 
stadiometer (Seca; Vogel & Halke, Hamburg, Germany). 
Weight and body composition were recorded with 
subjects wearing lightweight clothing and barefoot using a 
single-frequency segmental bioelectrical impedance analyser 
(BC-418 MA; Tanita Corp., Tokyo, Japan). Body mass 
index (BMI, kg/m2), fat-free mass (FFM), and fat mass (FM) 
were also determined. Waist and hip circumferences were 
measured with a stretch resistance tape.16
Pulmonary function tests
All the subjects completed spirometry and the FEV
1
, the forced 
vital capacity (FVC), and FEV
1
/FVC ratio were recorded 
(Vitalograph alpha, Bucks, UK). Patients were asked to with-
hold their inhaler medication including bronchodilators for at 
least 6 hours prior to their visit but were given 400 µg of salbu-
tamol through a spacer device 10 minutes prior to the test.
In the patients, breathlessness was scored using the modi-
fied Medical Research Council (mMRC) dyspnoea scale and 
the number of exacerbations, defined as an acute worsening 
of respiratory symptoms characterized by the increase of any 
combination of three key symptoms that necessitate a change 
in regular medication, was recorded in the last year.17
6MWD
The 6MWD was performed once in the subjects, and it was 
carried out in accordance with a protocol adapted from the 
American Thoracic Society guideline using a 30-m level, 
straight indoor track.18
TUg
All the subjects undertook the TUG test once (after dem-
onstration) using a standard chair (height of the seat being 
45 cm) and standardized instructions.11 Subjects were 
seated with their back supported against the chair. They 
were instructed to stand up, walk 3 m to a mark on the 
floor, cross the mark, turn around, walk back to the chair, 
and sit down. The task had to be performed at their normal 
comfortable pace. A stopwatch was started on the word 
“go” and stopped as the subject sat down; the time was 
recorded in seconds.
hand grip measurement
From a standing position with elbow extended, maximal 
right and left handgrip strength (HGS) was determined twice 
using a hand dynamometer, and the mean was calculated for 
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each hand (Takei equipment industrial T.K.K.5401 grip-D; 
Takei, Japan).
health-related questionnaire
Patients completed the St George’s Respiratory Question-
naire (SGRQ) and the COPD assessment test (CAT), both 
are validated questionnaires to assess the impact of COPD 
on their health status.19,20
Inlammatory biomarkers
A blood sample was obtained for the determination of 
C-reactive protein (CRP, high sensitivity) and fibrinogen 
by standard assays (Department of Biochemistry, University 
Hospital of Wales).
statistical analysis
The statistical software package SPSS 18.0 (SPSS Inc., 
Chicago, IL, USA) was used for all the analyses. Data were 
checked for normality prior to analysis. Parametric data were 
presented as mean and standard deviation or median (range) 
for nonparametric and categorical data. Comparisons between 
patients and controls were performed using analysis of 
variance. Categorical data were analyzed using the Chi-square 
test. Relationships between variables were explored using 
Pearson’s (r) and Spearman (r
s
) correlation coefficients. The 
correlation strength was classified as low (0–0.25), moderate 
(.0.25–0.50), strong (.0.50–0.75), and very strong (.0.75). 
Multivariate analysis was performed using a stepwise 
multiple regression model. For all the analysis, P,0.05 was 
considered significant. Receiver operating characteristics 
curve was performed to determine the diagnostic ability of 
the TUG test for the discrimination between stable patients 
with COPD and community population.
Results
The patients and controls were similar in age, sex ratio, and 
BMI. The patients had a greater tobacco exposure, lower 
mean FEV
1
, FVC, and resting oxygen saturation than the 
control group, all P,0.001 (Table 1). The severity of airflow 
obstruction by Global initiative for chronic Obstructive Lung 
Disease (GOLD) stratification was GOLD 1 n=70, GOLD 2 
n=269, GOLD 3 n=146, and GOLD 4 n=35. The patients were 
also subdivided according to GOLD quadrant based on the 
CAT score: GOLD A =40, GOLD B =128, GOLD C =26, 
and GOLD D =326.
Measures of physical performance
The patients had a greater TUG (mean ± standard devia-
tion: 11.5±4 seconds) than the controls (8.3±1.3 seconds, 
P=0.001), and 6MWD and HGS were less in patients 
than controls, both P,0.001 (Table 1). Across all the age 
decades ,49 – .70 years, the patients had greater TUG 
than the controls, P,0.001 (Figure 1). Using the upper 95% 
confidence interval (CI) for the control (8.42 seconds) as a 
cutoff value for the non-COPD range demonstrated that only 
92 of the 520 patients had a TUG within the control reference 
range; however, there was no difference in the TUG for males 
and females in either group. Across the GOLD quadrant, the 
TUG test was greater in group D, 12±4.9 seconds compared 
to group A, 8.9±2.4 seconds, and group C, 9.4±2.3 seconds, 
P,0.05, but was similar to group B, 11±4.4 seconds. Using the 
cutoff value of 8.42 seconds, only 12% of patients in group D 
and 15% of group B were below the reference range. Although 
groups A and C had good lung function, 45% of group A and 
69% of group C had greater TUG than the reference range.
The TUG was related to age in patients and controls 
(Table 2). In patients, the TUG was directly related to the 
FEV
1
% predicted, oxygen saturation, and modified Medical 
Research Council (mMRC) dyspnoea score and was inversely 
related to the 6MWD and HGS, whereas in the control group, 
Table 1 Characteristics of patients with COPD and control 
subjects
Variable COPD
(n=520)
Control
(n=150)
P-value
sex (male:female) 270:250 76:74 0.451
age (years) 66.1±7.6 65±7.4 0.109
FeV
1
/FVC (l) 0.53±0.11 0.78±0.05 ,0.001
FeV
1
 (% predicted) 58±19 105±14 ,0.001
FVC (% predicted) 87±21 109±15 ,0.001
smoking (pack-years) 41±25 22±18 ,0.001
BMI (kg/m2) 28.0±5.5 28.1±4.1 0.951
Waist circumference (cm) 99.6±15.0 94.7±10.2 0.001
hip circumference (cm) 104.2±11.0 105.0±8.7 0.250
Fat % 34.1±8.4 33.3±7.8 0.345
FFMI (kg/m2) 18.1±2.6 18.5±2.3 0.097
handgrip (kg) 27.1±9.7 31.3±10.3 ,0.001
TUg (seconds) 11.5±4 8.3±1.2 ,0.001
6MWD (m) 335±125 502±85 ,0.001
resting O
2
 saturation (%) 97±2 98±1 ,0.001
Fibrinogen (g/l)# 3.51±1.31 3.08±1.25 ,0.001
CrP (mg/ml)# 3.49±2.89 1.76±3.18 ,0.001
no exacerbations/year* 2 (1–3) – –
sgrQ total* 53 (36–68) – –
CaT score* 21 (14–27) – –
Notes: all data are mean (sD) unless otherwise indicated. *represents median 
(range) and #represents geometric mean. 
Abbreviations: 6MWD, 6-minute walk distance; BMI, body mass index; CaT, 
COPD assessment test; COPD, chronic obstructive pulmonary disease; CrP, 
C-reactive protein; FeV
1
, forced expiratory volume in 1 second; FVC, forced vital 
capacity; FFMI, fat-free mass index; sD, standard deviation; sgrQ, st george’s 
respiratory Questionnaire; TUg, timed up and go; –, not applicable.
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it was inversely related only to the 6MWD (Table 2). The 
6MWD, HGS, and TUG were all related to one another in 
the patients, P,0.001.
Body composition and the TUg test
In the patient group, the TUG was related to BMI, FM, FMI, 
and waist-to-hip ratio, whereas in the control group, it was 
only related to BMI and waist circumference (Table 2). Both 
TUG and 6MWD were related to FFM:FM ratio, r=-0.13, 
P=0.01, r=0.11, P=0.04, respectively, in the patient group, but 
only with 6MWD in the control group, r=0.34, P=0.001.
health-related questionnaires and 
TUg test
The TUG and the SGRQ total score were moderately 
related (r=0.37, P,0.001), as were the domains of activity 
(r=0.39, P,0.001), symptoms (r=0.39, P,0.001), and 
impact (r=0.32, P,0.001). The CAT score was also mod-
erately related to the TUG (r=0.37, P,0.001). Both the 
6MWD and HGS were also related to the total SGRQ score, 
r=-0.59 and r=-0.26, respectively (both P,0.001) and 
similar to the CAT score r=-0.53 and r=-0.27, respectively 
(both P,0.001).
Systemic inlammation
Circulating CRP and fibrinogen were greater in patients than 
in controls (P,0.001) and both were related to the TUG, 
CRP, r
s
=0.19, P=0.001, and fibrinogen, r
s
=0.17, P,0.001, 
but were unrelated to TUG in the control group. In the 
patients, 6MWD was also related to both CRP, r
s
=0.21, 
P=0.001, and fibrinogen, r
s
=-0.27, P=0.001, while neither 
biomarker was related to HGS. 
Frequency of exacerbation
Of the patients, 210 reported zero to one exacerbation/year and 
310 reported two or more exacerbations/year. The TUG was 
related to the frequency of exacerbations r
s
=0.24, P,0.001. 
Frequent exacerbators, 11.5±3.5 seconds, had greater TUG 
time than infrequent exacerbators, 10.6±3.9 seconds, and both 
were greater than the comparator group TUG. 
Predictive factors for the 6MWD
In the patients, stepwise multivariate regression analysis 
after controlling for age and BMI showed that TUG, mMRC, 
and CAT score explained 54% of the variability in 6MWD 
with FEV
1
% predicted excluded from the analysis, adjusted 
R2=0.54, P,0.001. The TUG explained 45% of the reduction 
in 6MWD and mMRC, and total CAT score explained 29% 
and 18% of the variability, respectively. 
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Figure 1 TUg test across age categories in COPD and control subjects.
Note: *P,0.001.
Abbreviations: COPD, chronic obstructive pulmonary disease; rOC, receiver operating characteristic; TUg, timed up and go.
Table 2 relationships between timed up and go test and other 
variables in patients and controls
Variable COPD P-value Control P-value
age (years) 0.18 0.005 0.22 0.001
FeV
1
% predicted -0.19 0.001 -0.04 0.610
resting O
2
 saturation (%) -0.12 0.005 -0.002 0.977
mMrC 0.34 0.001 – –
6MWD (m) -0.71 0.001 0.38 0.001
hgs (kg) -0.27 0.001 -0.02 0.833
BMI (kg/m2) 0.24 0.001 0.20 0.018
FM (kg) 0.21 0.001 0.12 0.141
FMI (kg/m2) 0.21 0.001 0.12 0.144
Abbreviations: 6MWD, 6-minute walk distance; BMI, body mass index; COPD, 
chronic obstructive pulmonary disease; hgs, handgrip strength; FeV
1
, forced 
expiratory volume in 1 second; FM, fat mass; FMI, fat mass index; mMRC, modiied 
Medical research Council; –, not applicable.
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Diagnostic ability of TUg test against 
6MWD
Using the upper 95% CI (8.42 seconds) of the TUG for 
the control as a cutoff value for normal mobility, the TUG 
test showed an excellent diagnostic ability to predict the 
6MWD as demonstrated by the area under the curve of 
0.826 (0.783–0.870) (Figure 2). With 90% sensitivity and 
80% specificity, this cutoff value corresponds to 360 m on 
the 6MWD.
Discussion
The TUG test is an integrated assessment of physical func-
tion, which incorporates balance, gait speed, and functional 
capacity.11 In the present study, the TUG was greater in 
patients with COPD than a non-COPD control group and 
similar to age-stratified ranges reported in a meta-analysis 
of 21 studies in the elderly.21 By comparing the 95% CI of 
both the groups, we suggest a cutoff point at 8.42 seconds 
or less for normal TUG test performance in this population. 
This threshold showed discriminative ability to identify 
patients with less physical performance with an area under 
the curve of 0.826. Similarly, the TUG test was found to 
predict mobility status and reflect physical performance 
with an area under the curve of 0.969 in community-
dwelling elderly women.22 Therefore, in clinical practice, 
patients who perform the TUG test in .8.42 seconds should 
receive a further evaluation of their physical status and early 
intervention to avoid subsequent complications related to 
physical inactivity.
A recent study showed that patients with COPD took 
longer time to perform the TUG than the controls, and a 
prolonged TUG identified patients with COPD at risk of 
falls.13 This is similar to the loss of physical performance, dis-
ability, and increased mortality risk shown in the elderly.23,24 
Unlike other field tests of lower limb function in COPD such 
as sit to stand test and gait speed test, which only measure 
one dimension of lower limb function, the TUG test is an 
integrated measure, and in addition to lower limb func-
tion assessment, it measures balance and mobility.25,26 Its 
prolongation in COPD is a consequence of impairment of 
physical activity, skeletal muscle weakness, and decondi-
tioning in a similar manner to that seen in the elderly. Thus 
in COPD, the TUG test is likely to reflect other measures 
of physical performance as well as the presence of comor-
bidities independent of the severity of airflow obstruction.4,13 
This is consistent with previous studies, where the TUG 
test measured the interaction of body composition, muscle 
strength, and comorbidities on the physical performance.13,22 
Hence, we explored the relationship of the TUG with the 
6MWD, a measure of submaximal exercise capacity, and 
HGS as a surrogate marker for muscle strength.27 Both the 
measures were related to TUG, particularly the 6MWD, 
which had a strong relationship, indicating that the TUG 
in COPD similarly assesses impaired functional mobility. 
Other studies have found a strong relationship between the 
TUG and the 6MWD in patients with other chronic disease 
such as heart failure.13,28 The prolonged TUG in our patients 
may reflect lower limb muscle weakness, and this is sup-
ported by the lower HGS, a surrogate measure of peripheral 
muscle strength, which was associated with reduced physical 
activity in COPD.29 In healthy elderly populations where it 
has been associated with reduced lower extremity strength 
and less daily activity and predicts future disability.30 The 
relationship between the increased TUG and SGRQ and CAT 
scores indicates that the TUG reflects the impact of physical 
impairment and inactivity on patients’ perceptions of their 
health and QoL.19,20
Altered body composition is an accepted comorbidity in 
COPD. Loss of skeletal muscle mass and function has been 
suggested as a cause of impaired physical function, similar 
to the sarcopenia and loss of physical function that occurs 
in healthy aging.31 Although FFM was not related to deficits 
in physical function in our study, changes in FM and its 
distribution were linked in both the controls and the patients. 
The TUG was related to abdominal obesity and FM, which is 
in line with studies showing that increased FM was the best 
predictor of functional limitation in COPD.32,33 This is sup-
ported by the UK study of the elderly similar to our cohort, 
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Figure 2 The rOC curve for the TUg test.
Note: Diagnostic ability of TUg test in patients with COPD.
Abbreviations: COPD, chronic obstructive pulmonary disease; rOC, receiver 
operating characteristic; TUg, timed up and go.
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which demonstrated that abdominal obesity determined as 
waist circumference was a major predictor of disability.34
The mechanisms linking FM and abdominal obesity to 
functional limitation may relate to the increased circulating 
levels of CRP and fibrinogen, which have been associated with 
reduced exercise capacity and left heart dysfunction in COPD. 
Circulating biomarkers, including CRP and fibrinogen, have 
been associated with physical decline and cardiovascular risk 
in older subjects.36 Fat produces various proinflammatory 
mediators including interleukin-6, a regulator of CRP produc-
tion and secretion, and is overall likely to be a factor in the 
development of insulin resistance and the increased risk of 
diabetes mellitus and cardiovascular disease in COPD.5
The association of TUG and systemic inflammation 
in our patients suggests that the components of physical 
function measured by this test have a similar relationship to 
other assessments used in COPD.35 Systemic inflammatory 
biomarkers may also be a factor linking the TUG to the fre-
quency of exacerbation when they are likely to increase.
The finding that the patients’ TUG was independent of 
age and was greater than in the control group when stratified 
by decades, and also published age ranges could be inter-
preted as the loss of physical performance in COPD being 
further evidence of premature aging and is in keeping with 
evidence of premature vascular aging.37 Such an interpreta-
tion is further supported by the finding that over 80% of our 
patient group had a greater TUG than the upper 95% CI of the 
control group. Confirming TUG as a valid indicator of dis-
ability in natural aging, a study in individuals over 85 years 
showed that having a TUG in the upper 10% percentile of 
a study population was associated with an increased risk of 
disability, odds ratio 9.02, and mortality.38 The predictive 
capacity of the TUG for similar outcomes in COPD will be 
an outcome of an ongoing prospective ARCADE study. 
The assessment of physical function and consequent 
disability is clinically important in the management of COPD. 
However, most measures of physical performance are dif-
ficult to apply in clinical practice. They often require sub-
stantial space, equipment, and staff time, and some patients 
may not be able to maintain activity long enough to complete 
an assessment. The rapidity and simplicity of the TUG test 
suggests that it could be used to assess physical performance 
in the routine clinical settings. Furthermore, in elderly, the 
TUG test has been found to be a responsive measure to a 
rehabilitation exercise program.39,40 Combining the TUG 
test with an easily completed validated questionnaire, such 
as the CAT, as demonstrated here, could provide important 
information about a patient’s physical performance and 
functional status that is not currently collected.
Limitations
A key limitation of this study is its cross-sectional nature, 
which limits understanding of the potential of this test in 
clinical practice. This issue is being addressed in a continuing 
longitudinal study (ARCADE). A limitation of measures of 
a number of physical functions is the requirement for time, 
space, and expertise. In addition, they may require substantial 
endurance, which limits the ability of patients to complete 
them. The short duration of TUG (ie, 1 minute including the 
instruction) removes the issues of endurance and resources 
that limit the application of some measures in COPD, and 
experience in the elderly suggests that it is a widely appli-
cable assessment.
Conclusion
This large study confirmed that TUG, a simple valid measure 
of physical performance, was greater in COPD than controls. 
Implementing the TUG test and questionnaires in clinical 
practice may improve the overall management of COPD. 
We recommend a TUG cutoff of .8.42 seconds to highlight 
individuals requiring further evaluation and management of 
their physical status.
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